Literature DB >> 12181257

Exacerbation of oxaliplatin neurosensory toxicity following surgery.

J-M Gornet1, E Savier, F Lokiec, E Cvitkovic, J-L Misset, F Goldwasser.   

Abstract

Combination of chemotherapy and surgical resection of metastases is the most promising strategy to improve the fraction of long-term survivors and cured patients in metastatic colorectal cancer. We reproducibly observed evidence of exacerbation of the oxaliplatin-induced neurosensory toxicity following surgery. Total, protein-bound and intra-erythrocytic concentrations of oxaliplatin were measured, whenever possible, immediately prior to surgery and 4, 24 and 48 h following surgical resection. Among 12 patients, seven (58%) patients reported immediate post-operative aggravation of the pre-existing neurotoxicity. At the time of surgery, we detected high intra-erythrocytic platinum concentrations in all patients (median: 1365 micro g/l, range: 820-2968 micro g/l). While ultrafilterable oxaliplatin was not detectable prior to surgery, it could be detected immediately after surgery and during 48 h. These results suggest that patients heavily pretreated with oxaliplatin may experience aggravation of neurotoxicity after surgery, probably through a redistribution of the pool of intra-erythrocytic oxaliplatin biotransformation products into the plasma. This clinical observation might be the consequence of peroperative hemolysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181257     DOI: 10.1093/annonc/mdf254

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  4 in total

1.  Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.

Authors:  Nicolas Williet; Olivier Dubreuil; Tarek Boussaha; Isabelle Trouilloud; Bruno Landi; Martin Housset; Muriel Botti; Philippe Rougier; Jacques Belghiti; Julien Taieb
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

Review 2.  Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Hana Starobova; Irina Vetter
Journal:  Front Mol Neurosci       Date:  2017-05-31       Impact factor: 5.639

3.  Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial.

Authors:  Likun Zhou; Rui Liu; Dingzhi Huang; Hongli Li; Tao Ning; Le Zhang; Shaohua Ge; Ming Bai; Xia Wang; Yuchong Yang; XinYi Wang; Xingyun Chen; Zhiying Gao; Laizhi Luo; Yuanquan Yang; Xi Wu; Ting Deng; Yi Ba
Journal:  EClinicalMedicine       Date:  2021-10-29

4.  Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.

Authors:  Yanyun Zhu; Junlan Yang; Shunchang Jiao; Tiefeng Ji
Journal:  World J Surg Oncol       Date:  2013-01-25       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.